ADC Therapeutics SA (ADCT) research
ADC Therapeutics SA- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $1.12
- As of
ADC Therapeutics SA (ADCT): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
As of . Source: SEC EDGAR filings for ADCT. Method and limitations.
Share the ADCT intelligence card
See ADCT live in the terminal
Track ADCT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ADCT terminal, freeActive signals for ADCT
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +13723% to ADCT (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 95% of ADCT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +60775% to ADCT (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +196% to ADCT (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +13723% to ADCT (2026Q2)
FREE, NO ACCOUNT
Every signal on ADCT, as it fires
You are seeing 5 of 21 signals recorded on ADCT since 2026-07-24.
The five above all landed on 2026-09-06. The other 16 were recorded on 2 other days. 20 of the 21 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ADCT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP H0036K147 · 2026Q2 | $3.9M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP H0036K147 · 2026Q2 | $3.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP H0036K147 · 2026Q2 | $2.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP H0036K147 · 2026Q2 | $828K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP H0036K147 · 2026Q2 | $770K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ADCT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ADCT against its peers
ADCT's operating margin of -149.3% ranks in the 9th percentile of 16 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | ADCT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 81.4M USD | 55.6M USD | 56 | 16 |
| Gross margin | n/a | 41.0% | n/a | 12 |
| Operating margin | -149.3% | -9.8% | 9 | 16 |
| Net margin | -175.3% | -31.2% | 8 | 17 |
| Return on equity | n/a | -31.9% | n/a | 14 |
Peers (18): GRUSF, AAWH, BGM, CPIX, DERM, CWBHF, TSNDF, JUSHF, CRDL, AKBA, ELTP, ZYBT, CRLBF, TLPH, LEEEF, SCYX, CGC, PLNH. Left out: ASRT (no annual filing), OGI (period gap), LFCR (no annual filing), CTOR (no annual filing), PHBI (period gap), INCR (period gap), BORAY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ADCT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ADCT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ADCTand get the insider, 13F, options, and confluence read in one view.